RxDoctor Payments Data

James Ruble, MD

Family Medicine · Mobile, ALNPI 1346256260

Payments from drug & device makers

$606in general payments, 2019–2025

Across 34 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$110
  • Sanofi-aventis U.S. LLC$97
  • Phathom Pharmaceuticals, Inc.$55
  • Lilly USA, LLC$51
  • Takeda Pharmaceuticals U.S.A., Inc.$37
  • Novo Nordisk$35
  • plus $220 from 11 others

What the payments were for

  • Food & beverage$606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$606 in reported general payments places this provider in the 45th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$63,525
Medicare patients
164
Services billed
3,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$76,304
MounjaroTirzepatide52$57,960
BiktarvyBictegrav/Emtricit/Tenofov Ala12$54,468
JardianceEmpagliflozin57$49,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$33,005
EliquisApixaban24$24,744
TrulicityDulaglutide16$19,581
JanuviaSitagliptin Phosphate18$16,645
JanumetSitagliptin Phos/Metformin Hcl17$16,104
TradjentaLinagliptin24$14,761
Breo ElliptaFluticasone/Vilanterol11$10,802
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen284$9,434
SynjardyEmpagliflozin/Metformin Hcl12$6,654
Atorvastatin Calcium391$4,482
Gabapentin184$4,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$51$77,54168 claims
Novo NordiskOzempic$35$76,30462 claims
GSKTrelegy Ellipta, Breo Ellipta$32$43,80638 claims
MerckJanuvia, Janumet$16$32,74935 claims
PfizerEliquis$11$24,74424 claims
AbbVieSynthroid$30$2,10339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →